FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004151829> ?p ?o ?g. }

• W2004151829 endingPage "861" @default.
• W2004151829 startingPage "847" @default.
• W2004151829 abstract "Multiple agents targeting the immune checkpoint programmed death-1 (PD-1) pathway have demonstrated early evidence of durable clinical activity and an encouraging safety profile in patients with various tumor types, including some cancers, such as non-small-cell lung cancer, historically perceived as non-immunogenic and thus nonresponsive to immunotherapy.Functions of the PD-1 pathway in normal immune responses are reviewed, along with the significance of expression of PD-1 and its ligands in malignant settings. Rationale for the development of PD-1 pathway-targeted therapies and associated clinical data are presented. Finally, efforts to date to identify and develop partner predictive or prognostic biomarkers for these new PD-1 pathway-targeted immunotherapies are discussed.Rather than targeting the tumor directly, immunotherapies inhibiting PD-1 pathway signaling modulate the antitumor immune response. Indeed, these agents have already demonstrated promising antitumor activity and manageable toxicity in various cancers. If future data continue to support encouraging clinical profiles of anti-PD-1 and anti-programmed death-ligand 1 antibodies, the current paradigm of cancer therapy may shift. In select patient populations (ideally identified by a predictive biomarker), PD-1 pathway-targeted immunotherapy has the potential to serve as the backbone of cancer treatment, and trials evaluating combinations with chemotherapy and/or molecularly targeted therapies will determine whether additive or even synergistic responses can be achieved." @default.
• W2004151829 created "2016-06-24" @default.
• W2004151829 creator A5028592995 @default.
• W2004151829 creator A5086473468 @default.
• W2004151829 date "2013-02-19" @default.
• W2004151829 modified "2023-09-30" @default.
• W2004151829 title "Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy" @default.
• W2004151829 cites W1519521580 @default.
• W2004151829 cites W1538902372 @default.
• W2004151829 cites W1568317937 @default.
• W2004151829 cites W1589049566 @default.
• W2004151829 cites W1929485758 @default.
• W2004151829 cites W1964080141 @default.
• W2004151829 cites W1966483230 @default.
• W2004151829 cites W1967084952 @default.
• W2004151829 cites W1976269164 @default.
• W2004151829 cites W1977523238 @default.
• W2004151829 cites W1983986735 @default.
• W2004151829 cites W1984198270 @default.
• W2004151829 cites W1984545852 @default.
• W2004151829 cites W1985106225 @default.
• W2004151829 cites W1985981664 @default.
• W2004151829 cites W1986354050 @default.
• W2004151829 cites W1994296136 @default.
• W2004151829 cites W2001131198 @default.
• W2004151829 cites W2002309260 @default.
• W2004151829 cites W2004495270 @default.
• W2004151829 cites W2010121426 @default.
• W2004151829 cites W2015085911 @default.
• W2004151829 cites W2016246963 @default.
• W2004151829 cites W2016732129 @default.
• W2004151829 cites W2016789384 @default.
• W2004151829 cites W2020727013 @default.
• W2004151829 cites W2021588881 @default.
• W2004151829 cites W2022580424 @default.
• W2004151829 cites W2022772800 @default.
• W2004151829 cites W2028376975 @default.
• W2004151829 cites W2029086221 @default.
• W2004151829 cites W2030259456 @default.
• W2004151829 cites W2030820484 @default.
• W2004151829 cites W2035012596 @default.
• W2004151829 cites W2042108941 @default.
• W2004151829 cites W2043115278 @default.
• W2004151829 cites W2044835625 @default.
• W2004151829 cites W2050302729 @default.
• W2004151829 cites W2053353274 @default.
• W2004151829 cites W2056535502 @default.
• W2004151829 cites W2057893793 @default.
• W2004151829 cites W2058870577 @default.
• W2004151829 cites W2060910588 @default.
• W2004151829 cites W2066607092 @default.
• W2004151829 cites W2068834940 @default.
• W2004151829 cites W2069274376 @default.
• W2004151829 cites W2069668866 @default.
• W2004151829 cites W2073310925 @default.
• W2004151829 cites W2073382063 @default.
• W2004151829 cites W2076067786 @default.
• W2004151829 cites W2087757222 @default.
• W2004151829 cites W2089228335 @default.
• W2004151829 cites W2091761329 @default.
• W2004151829 cites W2094366129 @default.
• W2004151829 cites W2097995306 @default.
• W2004151829 cites W2098853737 @default.
• W2004151829 cites W2100158834 @default.
• W2004151829 cites W2101653483 @default.
• W2004151829 cites W2101990345 @default.
• W2004151829 cites W2102575291 @default.
• W2004151829 cites W2105055793 @default.
• W2004151829 cites W2107598346 @default.
• W2004151829 cites W2107752337 @default.
• W2004151829 cites W2109550365 @default.
• W2004151829 cites W2109558684 @default.
• W2004151829 cites W2110695082 @default.
• W2004151829 cites W2111500154 @default.
• W2004151829 cites W2115918781 @default.
• W2004151829 cites W2118471749 @default.
• W2004151829 cites W2121596012 @default.
• W2004151829 cites W2121934915 @default.
• W2004151829 cites W2122639773 @default.
• W2004151829 cites W2124060252 @default.
• W2004151829 cites W2125988127 @default.
• W2004151829 cites W2128540669 @default.
• W2004151829 cites W2129806226 @default.
• W2004151829 cites W2130207101 @default.
• W2004151829 cites W2136313650 @default.
• W2004151829 cites W2138134458 @default.
• W2004151829 cites W2139591061 @default.
• W2004151829 cites W2140875987 @default.
• W2004151829 cites W2143381422 @default.
• W2004151829 cites W2143467222 @default.
• W2004151829 cites W2144953100 @default.
• W2004151829 cites W2146934919 @default.
• W2004151829 cites W2149336558 @default.
• W2004151829 cites W2150330457 @default.
• W2004151829 cites W2154610258 @default.
• W2004151829 cites W2155464214 @default.
• W2004151829 cites W2161558877 @default.
• W2004151829 cites W2162540156 @default.

• next